The drug discovery process, which involves the identification of a relevant biologica
...read moreWith several blockbuster therapies (such as Humira®, Rituxan®, Lantus®, A
...read moreAccording to a study published in the Canadian Journal of Infectious Disease and Medi
...read moreOver the last two decades, there have been several breakthroughs related to the devel
...read moreCurrently, biologics represent one of the fastest growing classes of the pharmaceutic
...read moreOver time, advances in manufacturing technologies have prompted pharmaceutical compan
...read moreSince the approval of Orthoclone OKT3, a murine monoclonal antibody against T cell ex
...read moreChronic diseases are considered to be the leading causes of deaths and disability. In
...read moreThe approval of three oral protein / peptide-based therapies has led to a substantial increase in the R&
...read moreCharacterized by a rapidly growing pipeline of biosimilars and novel biologics, and the existing challen
...read moreUpon realizing the potential of this route of administration, industry stakeholders have initiated sever
...read moreIn recent years, the potential of microbiome-based leads for the treatment of a myriad disease indicatio
...read moreReports
Major Pharma Markets
Clients
Analytical Frameworks
We are your partners with no equity
We fit in your budget
We love what we do
chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
.webp)
.webp)
.webp)
.png)
.png)
.png)
.png)
.png)
